BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates

Reuters01-13

** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O fall 12.26% to $20.91

** SRPT reports preliminary Q4 Elevidys net product revenue of $110.4 mln vs analysts' estimate of $176.99 mln, according to data compiled by LSEG

** Reports preliminary FY25 Elevidys net product revenue of $898.7 mln vs analysts' estimate of $1,029 mln

** "ELEVIDYS fourth-quarter revenue was impacted by severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026", co says

** Co reconfirms previously set yearly sales floor for ELEVIDYS of $500 million

** Stock had fallen 82.3% in 2025

(Reporting by Megha Anilkumar Nair)

((MeghaAnilkumar.Nair@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603283905?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603283905","market":"us","top_or_hot":-1,"title":"BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates </title></head><body><p>   ** Shares of genetic medicine maker <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> <span>SRPT.O</span> fall 12.26% to $20.91</p><p>** SRPT reports preliminary Q4 Elevidys net product revenue of $110.4 mln vs analysts' estimate of $176.99 mln, according to data compiled by LSEG</p><p>** Reports preliminary FY25 Elevidys net product revenue of $898.7 mln vs analysts' estimate of $1,029 mln</p><p>** \"ELEVIDYS fourth-quarter revenue was impacted by severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026\", co says</p><p>** Co reconfirms previously set yearly sales floor for ELEVIDYS of $500 million</p><p>** Stock had fallen 82.3% in 2025</p><p> (Reporting by Megha Anilkumar Nair)</p><p> ((MeghaAnilkumar.Nair@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 02:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates </title></head><body><p>   ** Shares of genetic medicine maker <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> <span>SRPT.O</span> fall 12.26% to $20.91</p><p>** SRPT reports preliminary Q4 Elevidys net product revenue of $110.4 mln vs analysts' estimate of $176.99 mln, according to data compiled by LSEG</p><p>** Reports preliminary FY25 Elevidys net product revenue of $898.7 mln vs analysts' estimate of $1,029 mln</p><p>** \"ELEVIDYS fourth-quarter revenue was impacted by severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026\", co says</p><p>** Co reconfirms previously set yearly sales floor for ELEVIDYS of $500 million</p><p>** Stock had fallen 82.3% in 2025</p><p> (Reporting by Megha Anilkumar Nair)</p><p> ((MeghaAnilkumar.Nair@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD1LW:1","article_id":"2603283905","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603283905","pubTimestamp":1768242611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates    ** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O fall 12.26% to $20.91** SRPT reports preliminary Q4 Elevidy","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","SRPT":"Sarepta Therapeutics"},"translate_title":"Elevidys第四季度初步收入未达预期后，BUZZ-Sarepta下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"BUZZ-Sarepta falls after preliminary Q4 Elevidys revenue misses estimates    ** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O fall 12.26% to $20.91** SRPT reports preliminary Q4 Elevidys net product revenue of $110.4 mln vs analysts' estimate of $176.99 mln, according to data compiled by LSEG** Reports preliminary FY25 Elevidys net product revenue of $898.7 mln vs analysts' estimate of $1,029 mln** \"ELEVIDYS fourth-quarter revenue was impacted by severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026\", co says** Co reconfirms previously set yearly sales floor for ELEVIDYS of $500 million** Stock had fallen 82.3% in 2025 (Reporting by Megha Anilkumar Nair) ((MeghaAnilkumar.Nair@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603283905","isCrawlerRequest":true}